323 related articles for article (PubMed ID: 25652132)
1. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.
Milara J; Morell A; Ballester B; Sanz C; Freire J; Qian X; Alonso-Garcia M; Morcillo E; Cortijo J
Respir Res; 2015 Feb; 16(1):12. PubMed ID: 25652132
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Milara J; Lluch J; Almudever P; Freire J; Xiaozhong Q; Cortijo J
J Allergy Clin Immunol; 2014 Aug; 134(2):314-22. PubMed ID: 24636089
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
5. Effects of budesonide on toll-like receptor expression in alveolar macrophages from smokers with and without COPD.
Ji J; von Schéele I; Billing B; Dahlén B; Lantz AS; Larsson K; Palmberg L
Int J Chron Obstruct Pulmon Dis; 2016; 11():1035-43. PubMed ID: 27274225
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells.
Victoni T; Gicquel T; Bodin A; Daude M; Tenor H; Valença S; Devillier P; Porto LC; Lagente V; Boichot E
Int Immunopharmacol; 2016 Jan; 30():1-8. PubMed ID: 26610096
[TBL] [Abstract][Full Text] [Related]
7. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.
Tyrrell J; Qian X; Freire J; Tarran R
Am J Physiol Lung Cell Mol Physiol; 2015 May; 308(10):L1068-77. PubMed ID: 25795727
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast partially reverses smoke-induced mucociliary dysfunction.
Schmid A; Baumlin N; Ivonnet P; Dennis JS; Campos M; Krick S; Salathe M
Respir Res; 2015 Oct; 16():135. PubMed ID: 26521141
[TBL] [Abstract][Full Text] [Related]
10. Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants.
Pomerenke A; Lea SR; Herrick S; Lindsay MA; Singh D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2409-2417. PubMed ID: 27729782
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphodiesterase 4 modulates cytokine induction from toll like receptor activated, but not rhinovirus infected, primary human airway smooth muscle.
Van Ly D; De Pedro M; James P; Morgan L; Black JL; Burgess JK; Oliver BG
Respir Res; 2013 Nov; 14(1):127. PubMed ID: 24237854
[TBL] [Abstract][Full Text] [Related]
12.
Nakamoto K; Watanabe M; Sada M; Inui T; Nakamura M; Honda K; Wada H; Ishii H; Takizawa H
Exp Lung Res; 2019 Oct; 45(8):255-266. PubMed ID: 31517562
[No Abstract] [Full Text] [Related]
13. Roflumilast N-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells.
Patel BS; Rahman MM; Baehring G; Xenaki D; Tang FS; Oliver BG; Ammit AJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):532-538. PubMed ID: 27997807
[TBL] [Abstract][Full Text] [Related]
14. Prostanoid Receptors of the EP
Joshi R; Hamed O; Yan D; Michi AN; Mostafa MM; Wiehler S; Newton R; Giembycz MA
J Pharmacol Exp Ther; 2021 Feb; 376(2):161-180. PubMed ID: 33158942
[TBL] [Abstract][Full Text] [Related]
15. Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.
Khorasani N; Baker J; Johnson M; Chung KF; Bhavsar PK
Int J Chron Obstruct Pulmon Dis; 2015; 10():283-91. PubMed ID: 25678784
[TBL] [Abstract][Full Text] [Related]
16. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
[TBL] [Abstract][Full Text] [Related]
18. Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells.
Higham A; Karur P; Jackson N; Cunoosamy DM; Jansson P; Singh D
Int J Chron Obstruct Pulmon Dis; 2018; 13():1279-1288. PubMed ID: 29719383
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
[TBL] [Abstract][Full Text] [Related]
20. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease.
Milara J; Díaz-Platas L; Contreras S; Ribera P; Roger I; Ballester B; Montero P; Cogolludo Á; Morcillo E; Cortijo J
Respir Res; 2018 Nov; 19(1):226. PubMed ID: 30458870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
